With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

In­sil­i­co Med­i­cine re­port­ed Phase 2a re­sults for its lead pro­gram, say­ing the study achieved its pri­ma­ry end­point of safe­ty and tol­er­a­bil­i­ty. But the ef­fi­ca­cy da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER